Objectives: To determine the prevalence of chronic urticaria in patients diagnosed with an allergic pathology; to know the most affected sex and age group.
Methods: A descriptive, observational, and retrospective cross-sectional study. Clinical records of patients diagnosed with chronic urticaria in Unidad de Medicina Integral (Integrated Care Unit) of Tehuacan, Puebla were reviewed. They were selected by age, sex, and diagnosed allergic pathology.
Results: In the period of January 1st, 2015, to December 31st, 2020, 373 patients were diagnosed with chronic urticaria, with a prevalence of 10.5%. The average age of the population was 26.05 years. Women were the most prevalent, with 59.5% of the total studied population.
Conclusions: The results reflect a prevalence of 10.5%, with a higher frequency in women at a ratio of 1.4: 1 with regard to males. The prevalence of chronic urticaria has increased significantly in recent years and especially in young patients (infants, preschoolers, and school-age children).
{"title":"[Prevalence of chronic urticaria in a medical unit].","authors":"Jorge Zamitiz-Hernández, Rodolfo Celio-Murillo, María Angélica Torres-Reyes, Reynaldo León-Aguilar, Vania Ramírez-González","doi":"10.29262/ram.v68i3.867","DOIUrl":"https://doi.org/10.29262/ram.v68i3.867","url":null,"abstract":"<p><strong>Objectives: </strong>To determine the prevalence of chronic urticaria in patients diagnosed with an allergic pathology; to know the most affected sex and age group.</p><p><strong>Methods: </strong>A descriptive, observational, and retrospective cross-sectional study. Clinical records of patients diagnosed with chronic urticaria in Unidad de Medicina Integral (Integrated Care Unit) of Tehuacan, Puebla were reviewed. They were selected by age, sex, and diagnosed allergic pathology.</p><p><strong>Results: </strong>In the period of January 1st, 2015, to December 31st, 2020, 373 patients were diagnosed with chronic urticaria, with a prevalence of 10.5%. The average age of the population was 26.05 years. Women were the most prevalent, with 59.5% of the total studied population.</p><p><strong>Conclusions: </strong>The results reflect a prevalence of 10.5%, with a higher frequency in women at a ratio of 1.4: 1 with regard to males. The prevalence of chronic urticaria has increased significantly in recent years and especially in young patients (infants, preschoolers, and school-age children).</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 3","pages":"174-179"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39507456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Martín Bedolla-Barajas, Jaime Morales-Romero, Tonantzin Isis Bedolla-Pulido, Miriam Montzerrat Flores-Razo, Marco Antonio Morales, Gustavo Rosales, Kevin Javier Arellano-Arteaga, Beatriz Alejandra Paz-Velarde
Objective: To determine the prevalence of blood eosinophilia in adults with chronic obstructive pulmonary disease (COPD) according to different cut-off points.
Methods: A cross-sectional study was carried out in patients with COPD. The frequency of blood eosinophilia was determined by absolute (cells/ µL) and relative (%) eosinophil count. Multivariate methods were used in order to identify the associated factors.
Results: 81 patients were included; the mean age was 71.9 ± 9.8 years; 46 (57%) of the patients were men. The prevalence of eosinophilia for the cut-off points of ≥ 100, ≥ 150, ≥ 200, ≥ 300, and ≥ 400 cells/µL was of 64.2%, 37.0%, 16.1%, and 9.9% respectively. Out of 81 patients, 34 (42%) had a relative eosinophil concentration of ≥ 2%; 21 (25.9%) ≥ 3%; 14 patients (17.3%) had ≥ 4%; and 10 patients (12.3%) had ≥ 5%. Eosinophilia of ≥ 100 cells/µL was associated with age of ≥ 80 years (OR = 6.04, p = 0.026), and with the exacerbation of COPD (OR = 9.40, p = 0.038); in contrast, eosinophilia of ≥ 2% was associated only with age of ≥ 80 years (OR = 3.73, p = 0.020). In addition, the eosinophil count of ≥ 100 and < 300 cells/µL was associated with the exacerbation of COPD (OR = 11.00, p = 0.026).
Conclusions: Our results suggest that the frequency of eosinophilia in the context of COPD shows substantial variations according to the used definition.
目的:了解成人慢性阻塞性肺疾病(COPD)患者血液嗜酸性粒细胞增多症的流行情况。方法:对慢性阻塞性肺病患者进行横断面研究。通过嗜酸性粒细胞绝对计数(细胞/µL)和相对计数(%)测定血嗜酸性粒细胞频率。采用多变量方法确定相关因素。结果:纳入81例患者;平均年龄71.9±9.8岁;男性46例(57%)。在≥100、≥150、≥200、≥300和≥400个细胞/µL的临界值下,嗜酸性粒细胞的患病率分别为64.2%、37.0%、16.1%和9.9%。81例患者中,34例(42%)的相对嗜酸性粒细胞浓度≥2%;≥3% 21例(25.9%);≥4% 14例(17.3%);≥5% 10例(12.3%)。嗜酸性粒细胞≥100个/µL与年龄≥80岁相关(OR = 6.04, p = 0.026),与COPD加重相关(OR = 9.40, p = 0.038);相反,嗜酸性粒细胞≥2%仅与年龄≥80岁相关(OR = 3.73, p = 0.020)。此外,嗜酸性粒细胞计数≥100和< 300 cells/µL与COPD加重相关(OR = 11.00, p = 0.026)。结论:我们的研究结果表明,COPD背景下嗜酸性粒细胞增多的频率根据所使用的定义显示出实质性的变化。
{"title":"[Prevalence of blood eosinophilia in adults with COPD according to the cut-off point].","authors":"Martín Bedolla-Barajas, Jaime Morales-Romero, Tonantzin Isis Bedolla-Pulido, Miriam Montzerrat Flores-Razo, Marco Antonio Morales, Gustavo Rosales, Kevin Javier Arellano-Arteaga, Beatriz Alejandra Paz-Velarde","doi":"10.29262/ram.v67i3.893","DOIUrl":"https://doi.org/10.29262/ram.v67i3.893","url":null,"abstract":"<p><strong>Objective: </strong>To determine the prevalence of blood eosinophilia in adults with chronic obstructive pulmonary disease (COPD) according to different cut-off points.</p><p><strong>Methods: </strong>A cross-sectional study was carried out in patients with COPD. The frequency of blood eosinophilia was determined by absolute (cells/ µL) and relative (%) eosinophil count. Multivariate methods were used in order to identify the associated factors.</p><p><strong>Results: </strong>81 patients were included; the mean age was 71.9 ± 9.8 years; 46 (57%) of the patients were men. The prevalence of eosinophilia for the cut-off points of ≥ 100, ≥ 150, ≥ 200, ≥ 300, and ≥ 400 cells/µL was of 64.2%, 37.0%, 16.1%, and 9.9% respectively. Out of 81 patients, 34 (42%) had a relative eosinophil concentration of ≥ 2%; 21 (25.9%) ≥ 3%; 14 patients (17.3%) had ≥ 4%; and 10 patients (12.3%) had ≥ 5%. Eosinophilia of ≥ 100 cells/µL was associated with age of ≥ 80 years (OR = 6.04, p = 0.026), and with the exacerbation of COPD (OR = 9.40, p = 0.038); in contrast, eosinophilia of ≥ 2% was associated only with age of ≥ 80 years (OR = 3.73, p = 0.020). In addition, the eosinophil count of ≥ 100 and < 300 cells/µL was associated with the exacerbation of COPD (OR = 11.00, p = 0.026).</p><p><strong>Conclusions: </strong>Our results suggest that the frequency of eosinophilia in the context of COPD shows substantial variations according to the used definition.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 3","pages":"152-159"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39507453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Luis Fernando Zavala-Jonguitud, Juan Carlos Anda, Miguel Guillermo Flores-Padilla, Carla Pérez, José Daniel Juárez-Villa
Objectives: The primary objective of this study was to define the relationship between vitamin D levels and interleukins (IL) 1β and 6 as inflammatory markers in a healthy population. As a secondary objective, to measure the prevalence of insufficiency/ deficiency of vitamin D in the same population.
Methods: A sample of 43 healthy blood donors, without chronic-degenerative, inflammatory, or infectious diseases, and without obesity, was selected. Serum levels of IL-1β and IL-6 were measured in individuals with insufficiency or deficiency of vitamin D. The correlation between vitamin D and interleukins was measured using Spearman's rho.
Results: No correlation was found between levels of vitamin D and interleukins. In addition, a prevalence of insufficiency/deficiency of vitamin D was found in 95.3% of the sample.
Conclusions: In healthy subjects with deficiency or insufficiency of vitamin D, there is no association between the levels of this vitamin and IL-1β and IL-6.
{"title":"[Correlation between insufficiency or deficiency of vitamin D levels and interleukins 1β and 6].","authors":"Luis Fernando Zavala-Jonguitud, Juan Carlos Anda, Miguel Guillermo Flores-Padilla, Carla Pérez, José Daniel Juárez-Villa","doi":"10.29262/ram.v68i3.885","DOIUrl":"https://doi.org/10.29262/ram.v68i3.885","url":null,"abstract":"<p><strong>Objectives: </strong>The primary objective of this study was to define the relationship between vitamin D levels and interleukins (IL) 1β and 6 as inflammatory markers in a healthy population. As a secondary objective, to measure the prevalence of insufficiency/ deficiency of vitamin D in the same population.</p><p><strong>Methods: </strong>A sample of 43 healthy blood donors, without chronic-degenerative, inflammatory, or infectious diseases, and without obesity, was selected. Serum levels of IL-1β and IL-6 were measured in individuals with insufficiency or deficiency of vitamin D. The correlation between vitamin D and interleukins was measured using Spearman's rho.</p><p><strong>Results: </strong>No correlation was found between levels of vitamin D and interleukins. In addition, a prevalence of insufficiency/deficiency of vitamin D was found in 95.3% of the sample.</p><p><strong>Conclusions: </strong>In healthy subjects with deficiency or insufficiency of vitamin D, there is no association between the levels of this vitamin and IL-1β and IL-6.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 3","pages":"180-184"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39507457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lina Castaño-Jaramillo, Carla Toledo-Salinas, David Mendoza
Objective: To clinically characterize the events of anaphylaxis in a third-level pediatric hospital.
Methods: 1148 clinical records were reviewed. Eventually, the information of 35 events of anaphylaxis in 20 patients was analyzed; three of them had multiple episodes of anaphylaxis.
Results: The median age for the anaphylactic episodes was 11 years (Interquartile range 10 years, Q1 = 5, Q3 = 15), predominantly in adolescents between the ages of 12 and 17 years, and there was a slight predominance in women. The most frequent clinical manifestations were cutaneous (86%), followed by respiratory (83%), cardiovascular (74%), and gastrointestinal (46%) alterations. Cardiac arrest was documented in three episodes; however, no anaphylaxis-related deaths were reported. The main triggers for anaphylaxis were food (34%), medications (29%), allergen-specific immunotherapy (14%), and latex (11%). In patients with perioperative anaphylaxis, the clinical behavior was severe. Epinephrine was administered in 27 out of the 35 events (77%), but only in 11 cases it was the first-line treatment. Systemic corticosteroids were the most frequently used treatment, followed by epinephrine and antihistamines.
Conclusions: The use of epinephrine, which is the mainstay of the treatment, is suboptimal; with a preferred use of second-line medications like corticosteroids. Clear protocols for the diagnosis and treatment of anaphylaxis, as well as continuous education of health personnel, are necessary.
{"title":"[Causes and treatment of anaphylaxis in a Mexican third-level pediatric hospital].","authors":"Lina Castaño-Jaramillo, Carla Toledo-Salinas, David Mendoza","doi":"10.29262/ram.v68i3.904","DOIUrl":"https://doi.org/10.29262/ram.v68i3.904","url":null,"abstract":"<p><strong>Objective: </strong>To clinically characterize the events of anaphylaxis in a third-level pediatric hospital.</p><p><strong>Methods: </strong>1148 clinical records were reviewed. Eventually, the information of 35 events of anaphylaxis in 20 patients was analyzed; three of them had multiple episodes of anaphylaxis.</p><p><strong>Results: </strong>The median age for the anaphylactic episodes was 11 years (Interquartile range 10 years, Q1 = 5, Q3 = 15), predominantly in adolescents between the ages of 12 and 17 years, and there was a slight predominance in women. The most frequent clinical manifestations were cutaneous (86%), followed by respiratory (83%), cardiovascular (74%), and gastrointestinal (46%) alterations. Cardiac arrest was documented in three episodes; however, no anaphylaxis-related deaths were reported. The main triggers for anaphylaxis were food (34%), medications (29%), allergen-specific immunotherapy (14%), and latex (11%). In patients with perioperative anaphylaxis, the clinical behavior was severe. Epinephrine was administered in 27 out of the 35 events (77%), but only in 11 cases it was the first-line treatment. Systemic corticosteroids were the most frequently used treatment, followed by epinephrine and antihistamines.</p><p><strong>Conclusions: </strong>The use of epinephrine, which is the mainstay of the treatment, is suboptimal; with a preferred use of second-line medications like corticosteroids. Clear protocols for the diagnosis and treatment of anaphylaxis, as well as continuous education of health personnel, are necessary.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 3","pages":"160-164"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39507454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Madelein Toledo, Alejandro Campos, Selma Scheffler-Mendoza, Ximena León-Lara, Hiromi Onuma-Zamayoa, Sara Espinosa, Marco Antonio Yamazaki-Nakashimada, Lizbeth Blancas-Galicia
Chronic granulomatous disease (CGD) is an inborn error of immunity caused by a defect in one of the components of the NADPH oxidase complex, which is responsible for generating reactive oxygen species (ROS) during the respiratory burst in phagocytes. The absence of ROS produced by NADPH oxidase in neutrophils and in macrophages leads to greater susceptibility to certain bacterial and fungal infections, and also to inflammatory manifestations due to a deregulated inflammatory response, which suggests that the ability to adequately regulate inflammatory signaling depends on ROS produced by NADPH oxidase. The disease course in patients with X-linked CGD is more severe, with recurrent invasive infections; in contrast, patients with non-classic CGD do not present invasive bacterial or fungal infections, but have more prominent inflammatory manifestations. The most frequent gastrointestinal manifestations are stomatitis, gingivitis, chronic diarrhea, liver abscesses that are similar to inflammatory bowel disease (IBD), and granulomas that can cause obstruction or stenosis in the esophagus, stomach or intestine. It has been observed that the deficiency of p40phox and ROS (non-classic CGD) are associated with greater susceptibility to colitis and the development of severe inflammation; therefore, it is presented that these proteins participate in the resolution of inflammation. In general, the inflammatory findings in CGD, including gastrointestinal manifestations, are seldom described. In international cohorts, manifestations that are similar to IBD are reported in up to 58% of patients with CGD; however, in the only Mexican cohort, its finding is described in only 4 out of 93 patients (4.3%). In this review, we summarize the gastrointestinal clinical findings of CGD, including infectious and inflammatory manifestations, emphasizing on the latter.
{"title":"[Infectious and inflammatory gastrointestinal manifestations of chronic granulomatous disease].","authors":"Madelein Toledo, Alejandro Campos, Selma Scheffler-Mendoza, Ximena León-Lara, Hiromi Onuma-Zamayoa, Sara Espinosa, Marco Antonio Yamazaki-Nakashimada, Lizbeth Blancas-Galicia","doi":"10.29262/ram.v68i3.860","DOIUrl":"https://doi.org/10.29262/ram.v68i3.860","url":null,"abstract":"<p><p>Chronic granulomatous disease (CGD) is an inborn error of immunity caused by a defect in one of the components of the NADPH oxidase complex, which is responsible for generating reactive oxygen species (ROS) during the respiratory burst in phagocytes. The absence of ROS produced by NADPH oxidase in neutrophils and in macrophages leads to greater susceptibility to certain bacterial and fungal infections, and also to inflammatory manifestations due to a deregulated inflammatory response, which suggests that the ability to adequately regulate inflammatory signaling depends on ROS produced by NADPH oxidase. The disease course in patients with X-linked CGD is more severe, with recurrent invasive infections; in contrast, patients with non-classic CGD do not present invasive bacterial or fungal infections, but have more prominent inflammatory manifestations. The most frequent gastrointestinal manifestations are stomatitis, gingivitis, chronic diarrhea, liver abscesses that are similar to inflammatory bowel disease (IBD), and granulomas that can cause obstruction or stenosis in the esophagus, stomach or intestine. It has been observed that the deficiency of p40phox and ROS (non-classic CGD) are associated with greater susceptibility to colitis and the development of severe inflammation; therefore, it is presented that these proteins participate in the resolution of inflammation. In general, the inflammatory findings in CGD, including gastrointestinal manifestations, are seldom described. In international cohorts, manifestations that are similar to IBD are reported in up to 58% of patients with CGD; however, in the only Mexican cohort, its finding is described in only 4 out of 93 patients (4.3%). In this review, we summarize the gastrointestinal clinical findings of CGD, including infectious and inflammatory manifestations, emphasizing on the latter.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 3","pages":"198-205"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39505980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Francisco Javier Turrubiates-Hernández, Jorge Hernández-Bello, Edith Oregón-Romero, Guillermo González-Estevez, José Francisco Muñoz-Valle
SARS-CoV-2 continues to infect thousands of people around the world. It has been established that the main transmission mechanism of this virus is via airborne route, which is why it initially infects the respiratory tract. Currently, the effectiveness of medications used against COVID-19 is limited, and although immunization programs have been initiated, there is international inequality in the distribution of vaccines. Accordingly, the search for adjuvant therapies continues to be an alternative for research. Supplementation with vitamin A has been associated to the decrease of mortality from infection; this effect could be mediated by retinoic acid (RA), which is the active metabolite of vitamin A that exerts immunomodulatory functions. According to preclinical studies, RA favors the production of secretory immunoglobulin A (IgA) in the respiratory tract. In addition to this, the retinol-binding protein has been correlated with the concentration of IgA and neutralizing antibodies in patients with influenza. Therefore, this review aims to address the involvement of vitamin A in the production of secretory IgA in the respiratory epithelium in order to highlight its potential protection against SARS-CoV-2 infection.
{"title":"[The involvement of vitamin A in the production of secretory IgA in the respiratory epithelium for potential protection against SARS-CoV-2 infection].","authors":"Francisco Javier Turrubiates-Hernández, Jorge Hernández-Bello, Edith Oregón-Romero, Guillermo González-Estevez, José Francisco Muñoz-Valle","doi":"10.29262/ram.v68i3.977","DOIUrl":"https://doi.org/10.29262/ram.v68i3.977","url":null,"abstract":"<p><p>SARS-CoV-2 continues to infect thousands of people around the world. It has been established that the main transmission mechanism of this virus is via airborne route, which is why it initially infects the respiratory tract. Currently, the effectiveness of medications used against COVID-19 is limited, and although immunization programs have been initiated, there is international inequality in the distribution of vaccines. Accordingly, the search for adjuvant therapies continues to be an alternative for research. Supplementation with vitamin A has been associated to the decrease of mortality from infection; this effect could be mediated by retinoic acid (RA), which is the active metabolite of vitamin A that exerts immunomodulatory functions. According to preclinical studies, RA favors the production of secretory immunoglobulin A (IgA) in the respiratory tract. In addition to this, the retinol-binding protein has been correlated with the concentration of IgA and neutralizing antibodies in patients with influenza. Therefore, this review aims to address the involvement of vitamin A in the production of secretory IgA in the respiratory epithelium in order to highlight its potential protection against SARS-CoV-2 infection.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 3","pages":"185-197"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39505977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anaí Ortega-Espinosa, Miguel Ángel Martínez-Benaiges, Norma Angélica Rojas-Pineda, Blanca María Morfín-Maciel
INTRODUCTION Heiner syndrome is a very rare but reversible lung disease caused by non-IgE-mediated hypersensitivity to cow's milk proteins resulting in an atypical pulmonary disease in babies and infants. Very few cases have been reported. Due to its heterogeneous manifestations, the diagnosis can be delayed since it can occur with chronic or recurrent infections of the upper or lower respiratory tract, fever, growth failure, or gastrointestinal symptoms. Pulmonary infiltrates can be mistaken for pneumonia, but Heiner's syndrome is refractory to antibiotic treatment. CASE REPORT We describe the case of a 1-month-old newborn baby whose main symptom was hematemesis, which is a rare symptom. The diagnosis was confirmed with the complete disappearance of the symptoms when milk and dairy products were strictly avoided. CONCLUSIONS The prognosis is favorable if a milk-free diet is begun early. Most children will tolerate cow´s milk within a few years.
{"title":"[Hematemesis in a newborn baby with Heiner syndrome. A case report].","authors":"Anaí Ortega-Espinosa, Miguel Ángel Martínez-Benaiges, Norma Angélica Rojas-Pineda, Blanca María Morfín-Maciel","doi":"10.29262/ram.v68i3.901","DOIUrl":"https://doi.org/10.29262/ram.v68i3.901","url":null,"abstract":"INTRODUCTION Heiner syndrome is a very rare but reversible lung disease caused by non-IgE-mediated hypersensitivity to cow's milk proteins resulting in an atypical pulmonary disease in babies and infants. Very few cases have been reported. Due to its heterogeneous manifestations, the diagnosis can be delayed since it can occur with chronic or recurrent infections of the upper or lower respiratory tract, fever, growth failure, or gastrointestinal symptoms. Pulmonary infiltrates can be mistaken for pneumonia, but Heiner's syndrome is refractory to antibiotic treatment. CASE REPORT We describe the case of a 1-month-old newborn baby whose main symptom was hematemesis, which is a rare symptom. The diagnosis was confirmed with the complete disappearance of the symptoms when milk and dairy products were strictly avoided. CONCLUSIONS The prognosis is favorable if a milk-free diet is begun early. Most children will tolerate cow´s milk within a few years.","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 3","pages":"209-213"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39505979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: In December 2019, a new coronavirus was identified as the causal agent of the 2019 coronavirus disease (COVID-19) with a wide clinical spectrum that goes from asymptomatic cases to critical and fatal cases. Its usual manifestations are fever, cough, and fatigue; although some cases present skin lesions.
Cases report: The first case was a 30-year-old woman with a history of controlled solar urticaria who presented erythematous and pruritic wheals in malar and cervical regions and extremities; associated with general malaise, headaches, and nausea, in whom the presence of COVID-19 was confirmed; her condition improved with a quadruple dose of antihistamines. The second case was a 47-year-old woman with a history of wasp sting anaphylaxis, without mastocytosis, who presented nasal congestion, headaches, and hypogeusia associated with generalized, erythematous, and pruritic wheals, with confirmation of COVID-19; her condition improved with quadruple doses of antihistamines.
Conclusions: Cutaneous manifestations associated with COVID-19 are frequent and can be classified as inflammatory and vascular. Among them, urticarial lesions occupy the fourth place, and although there could be some predominance of these in patients with a history of allergies, more studies are required to define an association.
{"title":"[Urticaria associated with COVID-19 in allergic patients. A case series].","authors":"Catalina López, Ricardo Cardona","doi":"10.29262/ram.v68i3.869","DOIUrl":"https://doi.org/10.29262/ram.v68i3.869","url":null,"abstract":"<p><strong>Introduction: </strong>In December 2019, a new coronavirus was identified as the causal agent of the 2019 coronavirus disease (COVID-19) with a wide clinical spectrum that goes from asymptomatic cases to critical and fatal cases. Its usual manifestations are fever, cough, and fatigue; although some cases present skin lesions.</p><p><strong>Cases report: </strong>The first case was a 30-year-old woman with a history of controlled solar urticaria who presented erythematous and pruritic wheals in malar and cervical regions and extremities; associated with general malaise, headaches, and nausea, in whom the presence of COVID-19 was confirmed; her condition improved with a quadruple dose of antihistamines. The second case was a 47-year-old woman with a history of wasp sting anaphylaxis, without mastocytosis, who presented nasal congestion, headaches, and hypogeusia associated with generalized, erythematous, and pruritic wheals, with confirmation of COVID-19; her condition improved with quadruple doses of antihistamines.</p><p><strong>Conclusions: </strong>Cutaneous manifestations associated with COVID-19 are frequent and can be classified as inflammatory and vascular. Among them, urticarial lesions occupy the fourth place, and although there could be some predominance of these in patients with a history of allergies, more studies are required to define an association.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 3","pages":"214-217"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39505984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bianca Coronado, Itzel Vianey Ochoa-García, Carlos Torres-Lozano, Antonio Quintero-Ramos, Margarita Ortega-Cisneros
Objective: To estimate the frequency of chronic urticaria in patients who attended an allergy service in a tertiary care hospital; in addition, the main clinical characteristics are described.
Methods: In a period of 7 months, a total of 96 patients who were over 18 years of age were analyzed; they had been diagnosed with chronic spontaneous urticaria and chronic inducible urticaria.
Results: The frequency of chronic urticaria was of 1.31 % (n=98); 53 % were associated with some allergic pathology, and 54 % showed an alteration in the paraclinical tests. Chronic spontaneous urticaria was found in 80 % of the patients; and in 62 % of them, the urticaria was associated with angioedema. Chronic urticaria was controlled in 19 % of the studied population with the use of a single antihistamine.
Conclusions: The frequency of chronic urticaria in our study was lower than the frequency reported nationwide.
{"title":"[Frequency and clinical characterization of chronic urticaria in a tertiary care hospital].","authors":"Bianca Coronado, Itzel Vianey Ochoa-García, Carlos Torres-Lozano, Antonio Quintero-Ramos, Margarita Ortega-Cisneros","doi":"10.29262/ram.v658i2.818","DOIUrl":"https://doi.org/10.29262/ram.v658i2.818","url":null,"abstract":"<p><strong>Objective: </strong>To estimate the frequency of chronic urticaria in patients who attended an allergy service in a tertiary care hospital; in addition, the main clinical characteristics are described.</p><p><strong>Methods: </strong>In a period of 7 months, a total of 96 patients who were over 18 years of age were analyzed; they had been diagnosed with chronic spontaneous urticaria and chronic inducible urticaria.</p><p><strong>Results: </strong>The frequency of chronic urticaria was of 1.31 % (n=98); 53 % were associated with some allergic pathology, and 54 % showed an alteration in the paraclinical tests. Chronic spontaneous urticaria was found in 80 % of the patients; and in 62 % of them, the urticaria was associated with angioedema. Chronic urticaria was controlled in 19 % of the studied population with the use of a single antihistamine.</p><p><strong>Conclusions: </strong>The frequency of chronic urticaria in our study was lower than the frequency reported nationwide.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 2","pages":"94-100"},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39418884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Se reportó un ejemplo del factor Bayes para evaluar el grado de evidencia de las hipotesis estadisticas de acuerdo a los datos de un estudio reciente de la presente revista
{"title":"[The use of the Bayes factor in clinical research of immunology and allergology].","authors":"","doi":"10.29262/ram.v658i2.884","DOIUrl":"https://doi.org/10.29262/ram.v658i2.884","url":null,"abstract":"Se reportó un ejemplo del factor Bayes para evaluar el grado de evidencia de las hipotesis estadisticas de acuerdo a los datos de un estudio reciente de la presente revista","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 2","pages":"150-151"},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39418826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}